Long Wei, Shi-Shuo Wang, Zhi-Guang Huang, Rong-Quan He, Jia-Yuan Luo, Bin Li, Ji-Wen Cheng, Kun-Jun Wu, Yu-Hong Zhou, Shi Liu, Sheng-Hua Li, Gang Chen
{"title":"TM9SF1 可促进膀胱癌细胞的生长和浸润。","authors":"Long Wei, Shi-Shuo Wang, Zhi-Guang Huang, Rong-Quan He, Jia-Yuan Luo, Bin Li, Ji-Wen Cheng, Kun-Jun Wu, Yu-Hong Zhou, Shi Liu, Sheng-Hua Li, Gang Chen","doi":"10.5306/wjco.v15.i2.302","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BC) is the most common urological tumor. It has a high recurrence rate, displays tutor heterogeneity, and resists chemotherapy. Furthermore, the long-term survival rate of BC patients has remained unchanged for decades, which seriously affects the quality of patient survival. To improve the survival rate and prognosis of BC patients, it is necessary to explore the molecular mechanisms of BC development and progression and identify targets for treatment and intervention. Transmembrane 9 superfamily member 1 (TM9SF1), also known as MP70 and HMP70, is a member of a family of nine transmembrane superfamily proteins, which was first identified in 1997. <i>TM9SF1</i> can be expressed in BC, but its biological function and mechanism in BC are not clear.</p><p><strong>Aim: </strong>To investigate the biological function and mechanism of <i>TM9SF1</i> in BC.</p><p><strong>Methods: </strong>Cells at 60%-80% confluence were transfected with lentiviral vectors for 48-72 h to achieve stable <i>TM9SF1</i> overexpression or silencing in three BC cell lines (5637, T24, and UM-UC-3). The effect of <i>TM9SF1</i> on the biological behavior of BC cells was then investigated through CCK8, wound-healing assay, transwell assay, and flow cytometry.</p><p><strong>Results: </strong>Overexpression of <i>TM9SF1</i> increased the <i>in vitro</i> proliferation, migration, and invasion of BC cells by promoting the entry of BC cells into the G2/M phase. Silencing of <i>TM9SF1</i> inhibited <i>in vitro</i> proliferation, migration, and invasion of BC cells and blocked BC cells in the G1 phase.</p><p><strong>Conclusion: </strong><i>TM9SF1</i> may be an oncogene in BC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 2","pages":"302-316"},"PeriodicalIF":2.6000,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10915948/pdf/","citationCount":"0","resultStr":"{\"title\":\"TM9SF1 promotes bladder cancer cell growth and infiltration.\",\"authors\":\"Long Wei, Shi-Shuo Wang, Zhi-Guang Huang, Rong-Quan He, Jia-Yuan Luo, Bin Li, Ji-Wen Cheng, Kun-Jun Wu, Yu-Hong Zhou, Shi Liu, Sheng-Hua Li, Gang Chen\",\"doi\":\"10.5306/wjco.v15.i2.302\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Bladder cancer (BC) is the most common urological tumor. It has a high recurrence rate, displays tutor heterogeneity, and resists chemotherapy. Furthermore, the long-term survival rate of BC patients has remained unchanged for decades, which seriously affects the quality of patient survival. To improve the survival rate and prognosis of BC patients, it is necessary to explore the molecular mechanisms of BC development and progression and identify targets for treatment and intervention. Transmembrane 9 superfamily member 1 (TM9SF1), also known as MP70 and HMP70, is a member of a family of nine transmembrane superfamily proteins, which was first identified in 1997. <i>TM9SF1</i> can be expressed in BC, but its biological function and mechanism in BC are not clear.</p><p><strong>Aim: </strong>To investigate the biological function and mechanism of <i>TM9SF1</i> in BC.</p><p><strong>Methods: </strong>Cells at 60%-80% confluence were transfected with lentiviral vectors for 48-72 h to achieve stable <i>TM9SF1</i> overexpression or silencing in three BC cell lines (5637, T24, and UM-UC-3). The effect of <i>TM9SF1</i> on the biological behavior of BC cells was then investigated through CCK8, wound-healing assay, transwell assay, and flow cytometry.</p><p><strong>Results: </strong>Overexpression of <i>TM9SF1</i> increased the <i>in vitro</i> proliferation, migration, and invasion of BC cells by promoting the entry of BC cells into the G2/M phase. Silencing of <i>TM9SF1</i> inhibited <i>in vitro</i> proliferation, migration, and invasion of BC cells and blocked BC cells in the G1 phase.</p><p><strong>Conclusion: </strong><i>TM9SF1</i> may be an oncogene in BC.</p>\",\"PeriodicalId\":23802,\"journal\":{\"name\":\"World journal of clinical oncology\",\"volume\":\"15 2\",\"pages\":\"302-316\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-02-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10915948/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World journal of clinical oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5306/wjco.v15.i2.302\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v15.i2.302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:膀胱癌(BC)是最常见的泌尿系统肿瘤:膀胱癌(BC)是最常见的泌尿系统肿瘤。它具有复发率高、导师异质性和耐化疗等特点。此外,几十年来,膀胱癌患者的长期生存率一直未变,严重影响了患者的生存质量。为了改善 BC 患者的生存率和预后,有必要探索 BC 发生和发展的分子机制,并确定治疗和干预的靶点。跨膜 9 超家族成员 1(TM9SF1)又称 MP70 和 HMP70,是九种跨膜超家族蛋白家族中的一员,于 1997 年首次被发现。目的:研究 TM9SF1 在 BC 中的生物学功能和机制:方法:用慢病毒载体转染汇合度为60%-80%的细胞48-72 h,使TM9SF1在三种BC细胞系(5637、T24和UM-UC-3)中稳定过表达或沉默。然后通过CCK8、伤口愈合试验、Transwell试验和流式细胞术研究了TM9SF1对BC细胞生物学行为的影响:结果:通过促进 BC 细胞进入 G2/M 期,过表达 TM9SF1 增加了 BC 细胞的体外增殖、迁移和侵袭。沉默TM9SF1可抑制BC细胞的体外增殖、迁移和侵袭,并阻止BC细胞进入G1期:结论:TM9SF1可能是BC的致癌基因。
TM9SF1 promotes bladder cancer cell growth and infiltration.
Background: Bladder cancer (BC) is the most common urological tumor. It has a high recurrence rate, displays tutor heterogeneity, and resists chemotherapy. Furthermore, the long-term survival rate of BC patients has remained unchanged for decades, which seriously affects the quality of patient survival. To improve the survival rate and prognosis of BC patients, it is necessary to explore the molecular mechanisms of BC development and progression and identify targets for treatment and intervention. Transmembrane 9 superfamily member 1 (TM9SF1), also known as MP70 and HMP70, is a member of a family of nine transmembrane superfamily proteins, which was first identified in 1997. TM9SF1 can be expressed in BC, but its biological function and mechanism in BC are not clear.
Aim: To investigate the biological function and mechanism of TM9SF1 in BC.
Methods: Cells at 60%-80% confluence were transfected with lentiviral vectors for 48-72 h to achieve stable TM9SF1 overexpression or silencing in three BC cell lines (5637, T24, and UM-UC-3). The effect of TM9SF1 on the biological behavior of BC cells was then investigated through CCK8, wound-healing assay, transwell assay, and flow cytometry.
Results: Overexpression of TM9SF1 increased the in vitro proliferation, migration, and invasion of BC cells by promoting the entry of BC cells into the G2/M phase. Silencing of TM9SF1 inhibited in vitro proliferation, migration, and invasion of BC cells and blocked BC cells in the G1 phase.
期刊介绍:
The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.